JP2024156779A5 - - Google Patents
Info
- Publication number
- JP2024156779A5 JP2024156779A5 JP2024122975A JP2024122975A JP2024156779A5 JP 2024156779 A5 JP2024156779 A5 JP 2024156779A5 JP 2024122975 A JP2024122975 A JP 2024122975A JP 2024122975 A JP2024122975 A JP 2024122975A JP 2024156779 A5 JP2024156779 A5 JP 2024156779A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- component
- pharmaceutically acceptable
- acceptable salt
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340927P | 2022-05-11 | 2022-05-11 | |
| US63/340,927 | 2022-05-11 | ||
| JP2023078608A JP7531656B2 (ja) | 2022-05-11 | 2023-05-11 | 化合物及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023078608A Division JP7531656B2 (ja) | 2022-05-11 | 2023-05-11 | 化合物及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024156779A JP2024156779A (ja) | 2024-11-06 |
| JP2024156779A5 true JP2024156779A5 (cg-RX-API-DMAC7.html) | 2026-05-18 |
Family
ID=86732694
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023078608A Active JP7531656B2 (ja) | 2022-05-11 | 2023-05-11 | 化合物及びその使用 |
| JP2024122975A Pending JP2024156779A (ja) | 2022-05-11 | 2024-07-30 | 化合物及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023078608A Active JP7531656B2 (ja) | 2022-05-11 | 2023-05-11 | 化合物及びその使用 |
Country Status (17)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3198317A1 (en) * | 2020-11-10 | 2022-05-19 | Kevin J. Wilson | Compounds and uses thereof |
| WO2025008060A1 (en) * | 2023-07-05 | 2025-01-09 | Janssen Pharmaceutica Nv | 1,6-naphthridine compounds as smarca2 inhibitors useful for the treatment of smarca4 deficient cancers |
| WO2025099307A1 (en) * | 2023-11-10 | 2025-05-15 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of diseases |
| US20250304542A1 (en) * | 2024-03-11 | 2025-10-02 | Enanta Pharmaceuticals, Inc. | Fused Heterobicyclic Antiviral Agents |
| WO2025209520A1 (zh) * | 2024-04-03 | 2025-10-09 | 深圳众格生物科技有限公司 | 一种化合物、包含其的药物组合物及其用途 |
| WO2025237242A1 (zh) * | 2024-05-14 | 2025-11-20 | 上海和誉生物医药科技有限公司 | 一种smarca2抑制剂及其应用 |
| CN118930537B (zh) * | 2024-07-23 | 2025-05-13 | 上海信诺维生物医药有限公司 | 一种抑制brm的化合物 |
| CN118930561B (zh) * | 2024-07-23 | 2025-04-08 | 上海信诺维生物医药有限公司 | 一种稠环化合物 |
| CN118908980B (zh) * | 2024-07-23 | 2025-04-08 | 上海信诺维生物医药有限公司 | 一种多环化合物 |
| WO2026046365A1 (zh) * | 2024-08-30 | 2026-03-05 | 上海齐鲁制药研究中心有限公司 | Smarca2抑制剂及其制备方法和用途 |
| WO2026057002A1 (zh) * | 2024-09-12 | 2026-03-19 | 江苏恒瑞医药股份有限公司 | 一种烯炔类化合物及其应用 |
| WO2026061424A1 (zh) * | 2024-09-18 | 2026-03-26 | 深圳众格生物科技有限公司 | 一种化合物、包含其的药物组合物及其用途 |
| WO2026131996A1 (en) * | 2024-12-17 | 2026-06-25 | Onco3R Therapeutics Bv | Fused azines for the treatment of cancer |
| WO2026158636A1 (zh) * | 2025-01-26 | 2026-07-30 | 江苏恒瑞医药股份有限公司 | 一种三环骨架芳酰胺类化合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007243466B2 (en) | 2006-04-26 | 2012-01-19 | F. Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
| US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| WO2015095788A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| SG10201900631TA (en) | 2014-08-01 | 2019-02-27 | Nuevolution As | Compounds active towards bromodomains |
| BR112022015110A2 (pt) | 2020-01-29 | 2022-11-08 | Foghorn Therapeutics Inc | Compostos e usos dos mesmos |
| BR112022015109A2 (pt) * | 2020-01-29 | 2022-11-08 | Foghorn Therapeutics Inc | Compostos e usos dos mesmos |
| WO2021155264A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155262A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| CA3198317A1 (en) | 2020-11-10 | 2022-05-19 | Kevin J. Wilson | Compounds and uses thereof |
-
2023
- 2023-05-11 AU AU2023270055A patent/AU2023270055A1/en active Pending
- 2023-05-11 CA CA3252955A patent/CA3252955A1/en active Pending
- 2023-05-11 PE PE2024002469A patent/PE20250261A1/es unknown
- 2023-05-11 EP EP23729898.9A patent/EP4522280A1/en active Pending
- 2023-05-11 WO PCT/US2023/021793 patent/WO2023220219A1/en not_active Ceased
- 2023-05-11 TW TW113141340A patent/TW202506693A/zh unknown
- 2023-05-11 JP JP2023078608A patent/JP7531656B2/ja active Active
- 2023-05-11 IL IL316531A patent/IL316531A/en unknown
- 2023-05-11 TW TW112117604A patent/TWI864749B/zh active
- 2023-05-11 AR ARP230101168A patent/AR129299A1/es unknown
- 2023-05-11 KR KR1020247041093A patent/KR20250024923A/ko active Pending
- 2023-05-11 US US18/315,526 patent/US12139487B2/en active Active
- 2023-05-11 CN CN202380053231.6A patent/CN119677738A/zh active Pending
-
2024
- 2024-07-30 JP JP2024122975A patent/JP2024156779A/ja active Pending
- 2024-10-25 US US18/926,578 patent/US20250066354A1/en active Pending
- 2024-11-07 CO CONC2024/0015229A patent/CO2024015229A2/es unknown
- 2024-11-07 JO JOJO/P/2024/0250A patent/JOP20240250A1/ar unknown
- 2024-11-08 MX MX2024013838A patent/MX2024013838A/es unknown
- 2024-11-11 DO DO2024000231A patent/DOP2024000231A/es unknown
- 2024-11-11 CL CL2024003450A patent/CL2024003450A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023512039A5 (cg-RX-API-DMAC7.html) | ||
| Wang-Gillam et al. | Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: a phase I dose escalation and expansion study | |
| Patnaik et al. | A first-in-human phase I study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 dimesylate), in patients with advanced cancer | |
| JP2023168298A5 (cg-RX-API-DMAC7.html) | ||
| JP2023512038A5 (cg-RX-API-DMAC7.html) | ||
| AU2018288060A1 (en) | IL-1beta binding antibodies for use in treating cancer | |
| JP2022082565A (ja) | がんを処置するための方法 | |
| JP2020515578A5 (cg-RX-API-DMAC7.html) | ||
| JP2022533578A5 (cg-RX-API-DMAC7.html) | ||
| Oostendorp et al. | Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors | |
| JP2023507190A5 (cg-RX-API-DMAC7.html) | ||
| JP2024529976A5 (cg-RX-API-DMAC7.html) | ||
| CN107148285A (zh) | 吡咯并苯并二氮杂*‑抗体缀合物 | |
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| JP2010523477A5 (cg-RX-API-DMAC7.html) | ||
| AR040367A1 (es) | Anticuerpos humanizados contra el receptor de linfotoxina beta | |
| ES2897782T3 (es) | Método de tratamiento de las enfermedades de la metástasis ósea, medicamentos para el tratamiento y método para predecir el resultado clínico del tratamiento de las enfermedades causadas por metástasis ósea | |
| Lupp et al. | Reevaluation of sst1 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-7 | |
| WO2020032231A1 (ja) | 免疫チェックポイント阻害薬の有効性を予測するためのバイオマーカー | |
| IL273387B1 (en) | Thylanstatin analogs | |
| JPWO2022270524A5 (cg-RX-API-DMAC7.html) | ||
| Draghici et al. | Paraneoplastic syndromes in digestive tumors: A review | |
| JP2020521786A5 (cg-RX-API-DMAC7.html) | ||
| HK1223547A1 (zh) | 癌症治疗方法 | |
| Alvarez et al. | Sensitivity of monoclonal antibodies to carcinoembryonic antigen, tissue polypeptide antigen, alpha-fetoprotein, carbohydrate antigen 50, and carbohydrate antigen 19-9 in the diagnosis of colorectal adenocarcinoma |